585 related articles for article (PubMed ID: 26790028)
1. Elevated hepatocyte growth factor expression as an autocrine c-Met activation mechanism in acquired resistance to sorafenib in hepatocellular carcinoma cells.
Firtina Karagonlar Z; Koc D; Iscan E; Erdal E; Atabey N
Cancer Sci; 2016 Apr; 107(4):407-16. PubMed ID: 26790028
[TBL] [Abstract][Full Text] [Related]
2. Dual inhibition of Akt and c-Met as a second-line therapy following acquired resistance to sorafenib in hepatocellular carcinoma cells.
Han P; Li H; Jiang X; Zhai B; Tan G; Zhao D; Qiao H; Liu B; Jiang H; Sun X
Mol Oncol; 2017 Mar; 11(3):320-334. PubMed ID: 28164434
[TBL] [Abstract][Full Text] [Related]
3. Sorafenib inhibits migration and invasion of hepatocellular carcinoma cells through suppression of matrix metalloproteinase expression.
Ha TY; Hwang S; Moon KM; Won YJ; Song GW; Kim N; Tak E; Ryoo BY; Hong HN
Anticancer Res; 2015 Apr; 35(4):1967-76. PubMed ID: 25862849
[TBL] [Abstract][Full Text] [Related]
4. Exosomes derived from HCC cells induce sorafenib resistance in hepatocellular carcinoma both in vivo and in vitro.
Qu Z; Wu J; Wu J; Luo D; Jiang C; Ding Y
J Exp Clin Cancer Res; 2016 Sep; 35(1):159. PubMed ID: 27716356
[TBL] [Abstract][Full Text] [Related]
5. Activation of the HGF/c-MET axis promotes lenvatinib resistance in hepatocellular carcinoma cells with high c-MET expression.
Fu R; Jiang S; Li J; Chen H; Zhang X
Med Oncol; 2020 Mar; 37(4):24. PubMed ID: 32166604
[TBL] [Abstract][Full Text] [Related]
6. Targeting the PD-L1/DNMT1 axis in acquired resistance to sorafenib in human hepatocellular carcinoma.
Liu J; Liu Y; Meng L; Liu K; Ji B
Oncol Rep; 2017 Aug; 38(2):899-907. PubMed ID: 28627705
[TBL] [Abstract][Full Text] [Related]
7. Sorafenib inhibits the hepatocyte growth factor-mediated epithelial mesenchymal transition in hepatocellular carcinoma.
Nagai T; Arao T; Furuta K; Sakai K; Kudo K; Kaneda H; Tamura D; Aomatsu K; Kimura H; Fujita Y; Matsumoto K; Saijo N; Kudo M; Nishio K
Mol Cancer Ther; 2011 Jan; 10(1):169-77. PubMed ID: 21220499
[TBL] [Abstract][Full Text] [Related]
8. MiR-21 mediates sorafenib resistance of hepatocellular carcinoma cells by inhibiting autophagy via the PTEN/Akt pathway.
He C; Dong X; Zhai B; Jiang X; Dong D; Li B; Jiang H; Xu S; Sun X
Oncotarget; 2015 Oct; 6(30):28867-81. PubMed ID: 26311740
[TBL] [Abstract][Full Text] [Related]
9. Arsenic trioxide potentiates the anti-cancer activities of sorafenib against hepatocellular carcinoma by inhibiting Akt activation.
Zhai B; Jiang X; He C; Zhao D; Ma L; Xu L; Jiang H; Sun X
Tumour Biol; 2015 Apr; 36(4):2323-34. PubMed ID: 25416439
[TBL] [Abstract][Full Text] [Related]
10. Activation of MET promotes resistance to sorafenib in hepatocellular carcinoma cells via the AKT/ERK1/2-EGR1 pathway.
Xiang QF; Zhan MX; Li Y; Liang H; Hu C; Huang YM; Xiao J; He X; Xin YJ; Chen MS; Lu LG
Artif Cells Nanomed Biotechnol; 2019 Dec; 47(1):83-89. PubMed ID: 30663411
[TBL] [Abstract][Full Text] [Related]
11. Activation of c-Jun predicts a poor response to sorafenib in hepatocellular carcinoma: Preliminary Clinical Evidence.
Chen W; Xiao W; Zhang K; Yin X; Lai J; Liang L; Chen D
Sci Rep; 2016 Mar; 6():22976. PubMed ID: 26964667
[TBL] [Abstract][Full Text] [Related]
12. IGF2 Is Up-regulated by Epigenetic Mechanisms in Hepatocellular Carcinomas and Is an Actionable Oncogene Product in Experimental Models.
Martinez-Quetglas I; Pinyol R; Dauch D; Torrecilla S; Tovar V; Moeini A; Alsinet C; Portela A; Rodriguez-Carunchio L; Solé M; Lujambio A; Villanueva A; Thung S; Esteller M; Zender L; Llovet JM
Gastroenterology; 2016 Dec; 151(6):1192-1205. PubMed ID: 27614046
[TBL] [Abstract][Full Text] [Related]
13. Inhibition of Akt reverses the acquired resistance to sorafenib by switching protective autophagy to autophagic cell death in hepatocellular carcinoma.
Zhai B; Hu F; Jiang X; Xu J; Zhao D; Liu B; Pan S; Dong X; Tan G; Wei Z; Qiao H; Jiang H; Sun X
Mol Cancer Ther; 2014 Jun; 13(6):1589-98. PubMed ID: 24705351
[TBL] [Abstract][Full Text] [Related]
14. Cooperative interaction of MUC1 with the HGF/c-Met pathway during hepatocarcinogenesis.
Bozkaya G; Korhan P; Cokaklı M; Erdal E; Sağol O; Karademir S; Korch C; Atabey N
Mol Cancer; 2012 Sep; 11():64. PubMed ID: 22962849
[TBL] [Abstract][Full Text] [Related]
15. Activation of phosphatidylinositol 3-kinase/AKT/snail signaling pathway contributes to epithelial-mesenchymal transition-induced multi-drug resistance to sorafenib in hepatocellular carcinoma cells.
Dong J; Zhai B; Sun W; Hu F; Cheng H; Xu J
PLoS One; 2017; 12(9):e0185088. PubMed ID: 28934275
[TBL] [Abstract][Full Text] [Related]
16. Synergistic effect of sorafenib and vitamin K on suppression of hepatocellular carcinoma cell migration and metastasis.
Ha TY; Hwang S; Hong HN; Choi YI; Yoon SY; Won YJ; Song GW; Kim N; Tak E; Ryoo BY
Anticancer Res; 2015 Apr; 35(4):1985-95. PubMed ID: 25862851
[TBL] [Abstract][Full Text] [Related]
17. Bufalin Reverses Resistance to Sorafenib by Inhibiting Akt Activation in Hepatocellular Carcinoma: The Role of Endoplasmic Reticulum Stress.
Zhai B; Hu F; Yan H; Zhao D; Jin X; Fang T; Pan S; Sun X; Xu L
PLoS One; 2015; 10(9):e0138485. PubMed ID: 26381511
[TBL] [Abstract][Full Text] [Related]
18. A microRNA-7/growth arrest specific 6/TYRO3 axis regulates the growth and invasiveness of sorafenib-resistant cells in human hepatocellular carcinoma.
Kabir TD; Ganda C; Brown RM; Beveridge DJ; Richardson KL; Chaturvedi V; Candy P; Epis M; Wintle L; Kalinowski F; Kopp C; Stuart LM; Yeoh GC; George J; Leedman PJ
Hepatology; 2018 Jan; 67(1):216-231. PubMed ID: 28833396
[TBL] [Abstract][Full Text] [Related]
19. Updates on the hepatocyte growth factor/c-Met axis in hepatocellular carcinoma and its therapeutic implications.
García-Vilas JA; Medina MÁ
World J Gastroenterol; 2018 Sep; 24(33):3695-3708. PubMed ID: 30197476
[TBL] [Abstract][Full Text] [Related]
20. Inactivation of hypoxia-induced YAP by statins overcomes hypoxic resistance tosorafenib in hepatocellular carcinoma cells.
Zhou TY; Zhuang LH; Hu Y; Zhou YL; Lin WK; Wang DD; Wan ZQ; Chang LL; Chen Y; Ying MD; Chen ZB; Ye S; Lou JS; He QJ; Zhu H; Yang B
Sci Rep; 2016 Aug; 6():30483. PubMed ID: 27476430
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]